



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(於百慕達註冊成立之有限公司)

(Stock Code/股份代號: 0460)

NOTIFICATION LETTER 通知信函

Dear Non-registered Holder (Note),

29 April 2025

Sihuan Pharmaceutical Holdings Group Ltd. (the "Company")

- Notice of Publication of Annual Report 2024 and Circular ("Current Corporate Communications") and Environmental, Social and Governance Report 2024 ("ESG Report 2024")

The English and Chinese versions of the Company's Current Corporate Communications and ESG Report 2024 are available on the Company's website at www.sihuanpharm.com and the HKExnews website of The Stock Exchange of Hong Kong Limited (the "HKEx") at www.hkexnews.hk. You may access the Current Corporate Communications by clicking "Investor Relations" section on the homepage of the Company's website, then selecting under "Financial Statements/ESG Information" for Annual Report 2024 and ESG Report 2024; and under "Announcements and Circulars" for the Circular.

For future corporate communications*, a notice of publication of the website version of corporate communications, in both English and Chinese, will be sent by the Company to Non-registered Holders by email or by post on the publication date of the corporate communications. In support of electronic communication by email, the Company recommends you to provide your bank, broker, custodian, nominees or CCASS participant (collectively, the "Intermediaries") through which your shares are held with your email address at any time in the future. If the Company does not receive your functional email address or postal address from your Intermediaries, no notice of publication of the website version of a corporate communication will be sent to you.

If you want to receive the printed version of the Current Corporate Communications, please complete the request form (the "Request Form") on the reverse side and return it to the Company c/o Tricor Investor Services Limited (the "Branch Share Registrar") by using the mailing label at the bottom of the Request Form (no need to affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the Branch Share Registrar is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. The Request Form may also be downloaded from the Company's website at www.sihuanpharm.com or the HKExnews website of the HKEx at www.hkexnews.hk.

Please note that by completing and returning the Request Form to request for the printed copy of the Current Corporate Communications, you will expressly indicate that you prefer to receive all future corporate communications of the Company in printed form.

Should you have any queries relating to any of the above matters, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding public holidays.

By Order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Note: This letter is addressed to Non-registered Holders ("Non-registered Holder" means such person or company whose shares are held in The Central Clearing and Settlement System and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive corporate communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Request Form on the reverse side.

* Corporate communications include but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位非登記持有人(附註):

四環醫藥控股集團有限公司(「本公司」)

- 2024年年報及通函(「本次公司通訊文件」)及2024年環境、社會及管治報告(「2024年ESG報告」)之發佈通知

本公司的本次公司通訊文件中、英文版本及2024年ESG報告已上載於本公司網站(www.sihuanpharm.com)及香港聯合交易所有限公司(「香港交易所」)披露易網站(www.hkexnews.hk), 歡迎瀏覽。閣下可在本公司網站主頁的「投資者關係」項下按「財報報告和ESG報告」閱覽2024年年報及2024年ESG報告;及按「公告及通函」閱覽通函。

本公司將於公司通訊文件刊發日期通過電子郵件或郵寄方式向非登記持有人發送日後公司通訊文件之網站版本的登載通知, 該通知將同時提供英文和中文版本。為支援通過電子郵件方式進行公司通訊, 本公司建議閣下今後隨時向其代持有股份之銀行、經紀、託管商、代理人或中央結算系統參與者(統稱「中介機構」)提供電郵地址。如本公司沒有從中介機構收到閣下的有效的電郵地址或郵寄地址, 本公司將不會向閣下發送公司通訊文件之網站版本的登載通知。

如閣下欲收取本次公司通訊文件之印刷本, 請填妥在本函背面的申請表格(「申請表格」), 並使用表格下方之郵寄標籤經由卓佳證券登記有限公司(「股份過戶登記分處」)寄回本公司(如在香港投寄, 毋須貼上郵票; 否則, 請貼上適當的郵票)。股份過戶登記分處地址為香港夏慤道16號遠東金融中心17樓。申請表格亦可於本公司網站(www.sihuanpharm.com)或香港交易所披露易網站(www.hkexnews.hk)內下載。

請注意, 填妥並交回要求本次公司通訊文件之印刷本的申請表格, 表示閣下明確表明願意接受本公司所有日後公司通訊文件之印刷本。

如閣下對本函內容有任何疑問, 請致電股份過戶登記分處電話熱線(852) 2980 1333, 辦公時間為星期一至五上午9時正至下午5時正(公眾假期除外)。

承董事會命
四環醫藥控股集團有限公司
主席兼執行董事
車馮升醫生

二零二五年四月二十九日

附註: 此函件乃向本公司之非登記持有人(「非登記持有人」指股份存放於中央結算及交收系統的人士或公司, 透過香港中央結算有限公司不時向本公司發出通知, 希望收到公司通訊文件)發出。如果閣下已經出售或轉讓所持有之本公司股份, 則無需理會本函件及所附申請表格。

* 公司通訊文件包括但不限於: (a)董事會報告、年度財務報表連同核數師報告及財務摘要報告(如適用); (b)中期報告及中期摘要報告(如適用); (c)會議通告; (d)上市文件; (e)通函; 及(f)代表委任表格。



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(於百慕達註冊成立之有限公司)

(Stock Code/股份代號: 0460)

Request Form 申請表格

To: **Sihuan Pharmaceutical Holdings Group Ltd. (the "Company")**
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

致: 四環醫藥控股集團有限公司(「本公司」)
經 卓佳證券登記有限公司
香港夏慤道16號
遠東金融中心17樓

I/We would like to receive **all** corporate communications⁽¹⁾ of the Company (the "Corporate Communications") as indicated below:

本人/我們希望以下列方式收取 貴公司之**全部**公司通訊文件⁽¹⁾:

(Please mark **ONLY ONE (X)** of the following boxes)

(請從下列選擇中, 僅在其中一個空格內劃上「X」號)

☐ to receive **the printed English version** of all Corporate Communications ONLY; OR
僅收取公司通訊文件之英文印刷本; 或

☐ to receive **the printed Chinese version** of all Corporate Communications ONLY; OR
僅收取公司通訊文件之中文印刷本; 或

☐ to receive **both printed English and Chinese versions** of all Corporate Communications.
同時收取公司通訊文件之英文及中文印刷本。

Signature(s):

簽署: _____

Contact telephone number:

聯絡電話號碼: _____

Date:

日期: _____

Notes 附註:

- Corporate communications include but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form. 公司通訊文件包括但不限於: (a)董事會報告、年度財務報表連同核數師報告及財務摘要報告(如適用); (b)中期報告及中期摘要報告(如適用); (c)會議通告; (d)上市文件; (e)通函; 及(f)代表委任表格。
- Please complete all your details clearly. 請 閣下清楚填妥所有資料。
- This letter is addressed to non-registered holders ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). 此函件乃向本公司之非登記持有人(「非登記持有人」指股份存放於中央結算及交收系統的人士或公司, 透過香港中央結算有限公司不時向本公司發出通知, 希望收到公司通訊文件)發出。
- Any form with more than one box marked (X), with no box marked (X), with no signature or otherwise incorrectly completed will be void. 如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確, 則本表格將會作廢。
- The above instruction will apply to the Corporate Communications to be sent to you until you notify to the Company c/o Tricor Investor Services Limited to the contrary or unless you have at anytime ceased to have shareholdings in the Company. 上述指示適用於發送予 閣下之所有公司通訊文件, 直至 閣下經由卓佳證券登記有限公司通知本公司另外之安排或任何時候停止持有本公司的股份。
- For the avoidance of doubt, we do not accept any special instructions written on this Request Form. 為免存疑, 任何在本申請表格上的額外手寫指示, 本公司將不予處理。



Please cut the mailing label and stick this on an envelope to return the Request Form to us.

No postage stamp is required if posted in Hong Kong.

閣下寄回此申請表格時, 請將此郵寄標籤剪貼於信封上。

如在本港投寄, 閣下無需支付郵費或貼上郵票

Tricor Investor Services Limited
卓佳證券登記有限公司
Freeport No. 簡便回郵號碼: 10 GPO
Hong Kong 香港